Antimalarial Exporter in India
If you are seeking the best-known Antimalarial Exporter in India, then Actizapharma is one of the leading Antimalarial/ malaria medications and product ranges. We offer you Antimalarial medicines that include tablets, capsules, injectables, syrups, dry syrups, and more. Our pharma company is a dedicated Antimalarial medicine manufacturer and supplier in India. Our full range of Antimalarial medications is found with us at affordable costs under the best manufacturing services. People can get the highest-quality and professionalism with perfection at Actiza Pharma.
We ate Actiza Pharma is fully dedicated to exporting and manufacturing pharmaceuticals that come with disinfection. Since our leading Antimalarial Exporter in India, we are meticulous about sustaining the best quality of our wide-ranging medications so that they can easily go well with international standards. Our pharma company manufactures and exports Antimalarial treatment medicines at the best possible rates, and also it is accessible generally to all affected people.
We are one of the well-established manufacturers of medicines committed to cure cancer, as we also incorporate a whole range of medicines such as tablets, capsules, injections, and ointments. Our entire medications are utilized in immunotherapy, surgery, chemotherapy, or hormone therapy. Like other medicine manufacturing procedures, our Antimalarial medications are made in a stringent hygienic environment. We also keep the cleanliness of top standards similar to international standards. Some formulations are done in our facility with various oral Antimalarial tablets.
Our facilities Accredited & Complied
With WHO-GMP standards, We offer seamless service from the Plant registration to Development/Registration, and Commercialisation of the products globally
40+
Exporting Countries
12+
Years Of Experience
500+
Clients Globally
2000+
Product Lines
550+
Ready Dossiers
Have a query, send us a quick enquiry
* We will contact you shortly over an Email or Phone.
Overview of Malaria and Global Burden
Malaria is one of the significant public health issues across areas, including tropical zones together with subtropical zones.
This disease is spread by plasmodium parasites through the transmission between infected mosquitoes that belong to the Anopheles genus.
As per the WHO reports, Malaria affects more than 200 million people during each annual period.
It is also known that Malaria affects a great amount of people in Africa.
The region of South Asia, particularly India, experiences significant challenges in malaria control.
Effective results happen when treatment requirements unite with preventive approaches.
India’s Role in Antimalarial Drug Production & Export
The total hydroxychloroquine antimalarial drugs produced by India supply 70% of the global market.
Main countries receive hydroxychloroquine medications through these specific distribution patterns in export volume.
- United States: Approximately 47%
- South Africa: About 3.8%
- United Kingdom: Roughly 3.06%
- Brazil: Around 2.5%
- The antimalarial drug statistics from Nepal and Sri Lanka represent around 5% of global numbers.
The revenue from pharmaceutical exports in India reached $27.9 billion during fiscal year 2023-24.
Antimalarial medication production generates substantial market worth.
India utilizes the strategic export method to deliver medication that addresses global health requirements.
Through the export of antimalarial drugs India establishes improved diplomatic alliances with both international governments and worldwide diplomatic institutions.
Overview of Antimalarial Drugs
Drugs belonging to the antimalarial groups demonstrate successful anti-Plasmodium species performance. Common types include:
The primary treatment approach for Plasmodium falciparum malaria patients uses Artemisinin-based Combination Therapies products.
The medications Artemether-Lumefantrine and Artesunate-Mefloquine form part of its drug utilization.
Chloroquine and Hydroxychloroquine – Used for Plasmodium vivax and Plasmodium malarial infections.
Medical institutions depend on Primaquine to stop the recurrence of Plasmodium vivax malaria infections.
Quinine and Mefloquine – Used in cases of severe Malaria or drug-resistant strains.
India’s Antimalarial Export Market: Data & Statistics
The antimalarial drug exports from India reach substantial commercial volumes.
Worldwide malaria control programs depend heavily on the important role India provides in their operations.
The pharmaceutical industry in India distributes antimalarial medications to more than 100 international markets.
The Pharmaceutical Export Promotion Council (Pharmexcil) has published reports about these exports. In recent years:
The antimalarial medication exports from India generate annual revenues exceeding $500 million.
The antimalarial exports from India make up 50% of its total market.
India delivers more than 70% of global ACT supply to perform vital duties for WHO’s malaria eradication programs.
What is the need for antimalarial drugs?
Antimalarial medications have a widespread demand across the world.
Multiple influential variables demonstrate the absolute requirement for antimalarial medicines.
High malaria prevalence in Africa, South Asia, and parts of South America.
The growth of antimalarial drug resistance demands scientists to develop new treatment medications.
The WHO introduced the Global Technical Strategy for Malaria 2016–2030, which operates as a worldwide health program.
The need for preventive and curative medicines in endemic regions.
Key Players: Leading Antimalarial Exporters in India
Many Indian pharmaceutical firms hold the primary position for manufacturing and distributing antimalarial drugs throughout the export market.
Here are multiple pharmaceutical companies that form the core group of India’s antimalarial exporters:
- Actiza Pharma – One of the major quality and leading producers of antimalarials.
- Cipla Limited serves the market by manufacturing ACTs which they distribute to Africa and Asia.
- Ipca Laboratories – A leading supplier of Artemisinin-based medications.
- Zydus Cadila: It operates as a manufacturer that produces diverse malaria medicines.
- Lupin Pharmaceuticals – Active in research and development of new antimalarial drugs.
- Sun Pharma: This pharmaceutical company distributes its generic along with branded antimalarial medications throughout the global market.
Regulatory Framework for Antimalarial Exports from India
Indian pharmaceutical companies export their antimalarial medications and other medications. They do so under strict regulatory framework guidelines.
Drug Controller General of India (DCGI) – Ensures drug quality and compliance with GMP.
WHO Prequalification Programme: Indian pharmaceutical companies collaborate with WHO, Pharmexcil, and CDSCO regulations.
They have certifications that let them join global malaria control programs by giving out drugs.
Challenges in antimalarial drug exports
India has many barriers that stop the growth of antimalarial drug exports, even though it leads the market.
International countries present conflicting policies that govern imported goods.
Drug-resistant malaria strains have appeared, so research and development efforts must persist.
The pharmaceutical industry is now more competitive. This is due to China and other production hubs growing their operations.
Sales distribution issues in the supply chain need quick fixes. They cause delays in medication reaching places where Malaria is common.
The changing prices of raw materials make it hard for poor countries to buy medication at lower rates.
Future Outlook & Growth Opportunities
The antimalarial drug market in India will expand due to rising worldwide demand. Key opportunities include:
Expansion of WHO and Global Fund partnerships.
Development of newer, more effective antimalarial drugs.
Pharmaceutical companies should allocate more funds to resistive drug development research.
The organization wants to open new export channels in Latin America and Southeast Asia.
Conclusion
India plays a key role in global antimalarial drug efforts. It makes and supplies high-quality medicines at low prices.
India will stay at the top of the global antimalarial drug market.
This is thanks to ongoing innovation, meeting regulations, and strong international partnerships.
Drugs that resist treatment and regulatory issues need focused strategies.
These strategies aim to maintain market growth and improve malaria control programs worldwide.